RELATIVITY-047 4-Year Update: Nivolumab + Relatlimab in Advanced Melanoma
Did you know: At the 4-year mark, 52% of patients treated with the nivolumab and relatlimab fixed-dose combination remain alive. As the first-line treatment landscape for advanced melanoma evolves, achieving durable, long-term survival while maximizing time off-treatment has become the new clinical benchmark.
This essential infographic summarizes the 48-month data from the RELATIVITY-047 trial, providing Canadian melanoma specialists with a clear look at the long-term efficacy and safety profile of this dual-checkpoint inhibition.
What You Will Learn:
- Review current evidence and clinical guidelines for first-line therapy options in advanced melanoma.
- Evaluate key patient-specific factors (e.g., tumor characteristics, comorbidities, genetic markers, and performance status) that influence treatment selection.
- Discuss the role of shared decision-making in aligning treatment plans with patient values, preferences, and quality-of-life considerations.
- Apply evidence-based strategies to optimize individualized care in the first-line treatment setting
Download the Infographic to transform your first-line clinical decision-making and enhance long-term survivorship strategies for your patients.
Supported by unrestricted educational funding from Bristol-Myers Squibb.
